Macroaxis: Personalized Investing
Personalized Investing and
Digital Wealth Optimization

NVO TEVA AGN FRX ILS Bitcoins Currently Hot Music and Video Hybrid Mix 
Benchmark SP 500  1,652   12.77  Index Moved Up 0.78% United States ...


Processing
Collecting data for SCLN

SciClone quote and profile

 
 Companies |  Insiders  | Dashboard  
     
4.87
  
STOCK
0.00  No Change   0.00%  
Year To Date
3.687.58
Last 1 Month(s)
4.774.99
Trading Day 
4.844.92
June 19 2013 

Diversification Suggestion

Use SciClone to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Analyze SciClone Pharmaceuticals Trend or Check current 30 days SciClone correlation with market (S&P 500)
1 Month Beta 0.97  
Highest Price:  
Lowest Price:  
4.99  
4.77  
June 03 2013 
May 22 2013 
SciClone returns are very sensitive to returns on the market. As market goes up or down, SciClone is expected to follow.
SciClone Pharmaceuticals Inc llmost one BetaSciClone Pharmaceuticals Beta Legend
SCLN United States Nasdaq
SciClone Pharmaceuticals Inc
Healthcare
Drug Manufacturers - Other
Benchmark S&P 500
http://www.sciclone.com
Contact Number: 650. 358. 3456
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation179.7 M
Shares Outstanding54.01 M
Number of Shares Shorted3.2 M
Revenue156.27 M
 United States Russel   1.23 % Macroaxis: change 1.23 Moved Up  
 
 United States SP 500   0.78 % Macroaxis: 0.78 Moved Up  
 
 United States NYSE   0.66 % Macroaxis: 0.66 Moved Up  
 
 thisGreen SCLN SCLN agains markets  0.00 % No Change  
Compare to Competition Alpha & Beta   Get Advice

SciClone Leadership

Mark Lotter CEO of China Operations and Director
Friedhelm Blobel CEO and President and Director, Ph.D
Hong Zhao CEO of China Operations
Jon Saxe Independent Chairman of the Board

SciClone Price and Market Media

The median price of SciClone for the period between Mon, May 20, 2013 and Wed, Jun 19, 2013 is 4.88 with a coefficient of variation of 1.27. The daily time series for the period is distributed with a sample standard deviation of 0.06, arithmetic mean of 4.9, and mean deviation of 0.05. The Stock received substential amount of media coverage during this period.
SciClone         SP 500
Price Growth (%)
 
Change Benchmark  Embed  Export  Timeline
1
SCICLONE PHARMACEUTICALS INC. SciClone to Present at Jefferi...05/29/2013Macroaxis: News
2
Tech stocks Vs Pharmaceuticals Stocks Applied Materials Broc...06/04/2013Macroaxis: News
3
SciClone Pharmaceuticals Inc. Insiders Are Buying Should You06/07/2013Macroaxis: News
4
See How SciClone Pharmaceuticals Ranks Among Analyst Top Pic...06/11/2013Macroaxis: Forbes News

SciClone Summary

SciClone Pharmaceuticals Inc [SCLN] is traded on NASDAQ in USA. It is located in SciClone Pharmaceuticals, Inc.Foster City, CA and employs 870 people. The company currently falls under 'Small-Cap' category with current market capitalization of 262.48 M. SciClone Pharmaceuticals Inc conducts business under Healthcare sector and is part of Drug Manufacturers - Other industry. This company has 54.01 M outstanding shares of which 3.2 M shares are at this time shorted by private and institutional investors with about 11.5 trading days to cover.
SciClone Pharmaceuticals, Inc. offer therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People?s Republic of China and internationally. more
Past Market
Over 30
Days
1
Out Of
100
 
Chance of
Less
Than
%
 
Follow SciClone with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add SciClone to your reader
 

SciClone Research Report

SciClone vs. Novo

Correlation analysis and fundamentals comparison between SciClone Pharmaceuticals and Novo Nordisk A-S

SciClone Executives

Gary CPA CFO, Principal Accounting Officer and Sr. VP of Fin.
Lan Xie VP of Fin. and CFO of China Operations
Jackie Guan COO of China Operations

SciClone Directors

Gregg Lapointe Independent Director
Ira Lawrence Independent Director
Simon Li Director, MBA
Peter Barrett Independent Director, Ph.D
Richard Hawkins Independent Director

SciClone Management

Robert King VP of Product Devel. and Manufacturing
Min Yin VP of Compliance and Internal Audit

SciClone Fundamentals

Operating Margin vs Shares Owned by Insiders
Total Asset vs Current Ratio
Operating Margin vs Price to Book
Current Liabilities vs Current Ratio

SciClone vs Competition

SciClone vs. Novo Nordisk A-S
SciClone vs. Allergan Inc
SciClone vs. Cubist Pharmaceuticals Inc

SciClone June 19 2013 Opportunity Range

Downside Deviation1.53
Information Ratio0.04
Maximum Drawdown6.61
Value At Risk(2.21)
Potential Upside3.74

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium